Physician

Robert William Levin, M.D.

According to 2025 Medicare claims, Robert Levin, M.D. (NPI: 1326066903) practices rheumatology in the St. Petersburg-Clearwater-Largo, FL market, with the plurality of this provider's patient population coming from Pinellas, FL. This provider's primary affiliated billing organization is AMERICAN ARTHRITIS & RHEUMATOLOGY ASSOCIATES LLC (NPI: 1598205072; TIN: 831053374) and primary practice location at 33765-1450.

Levin's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 400 traditional Medicare patients, billed 174,138 HCPCS/CPT codes, and received $2,193,511 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,405 prescription claims across 546 beneficiaries totaling $1,493,082 in drug costs, led by Rinvoq (Upadacitinib). 2022 DME data shows 12 claims. Open Payments data shows 334 records totaling $1,080,412. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,493,570 to $2,193,511. Similarly, Part D prescription costs have risen steadily, from $737,617 to $1,493,082. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	683	119,473	$1,493,570
2016	664	113,959	$1,434,592
2017	641	127,207	$1,645,790
2018	613	125,615	$1,846,545
2019	594	136,927	$2,081,237
2020	577	176,436	$2,795,949
2021	573	139,497	$2,617,632
2022	509	135,162	$2,034,273
2023	435	142,809	$1,877,843
2024	400	174,138	$2,193,511

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	453	3,830	$737,617
2016	464	3,752	$644,298
2017	444	3,557	$767,361
2018	497	2,988	$828,976
2019	488	2,567	$609,871
2020	491	2,845	$662,982
2021	476	3,011	$932,083
2022	546	3,218	$1,172,047
2023	532	3,249	$1,128,833
2024	546	3,405	$1,493,082

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	11	$331
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	12	$1,239
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	238	532	$92
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	179	750	$52
J0897	Injection, denosumab, 1 mg	146	14,100	$21
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	223	536	$12
36415	Insertion of needle into vein for collection of blood sample	182	381	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Rinvoq	Upadacitinib	46	1,560	$349,420
Humira(Cf) Pen	Adalimumab	31	868	$229,603
Enbrel	Etanercept	27	756	$194,048
Simponi	Golimumab	12	360	$84,961
Xeljanz Xr	Tofacitinib Citrate	16	480	$83,947

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	264	$65,728	GENZYME CORPORATION
Research Payments	Reported research-related payment or transfer-of-value amount.	70	$1,014,683	E.R. Squibb & Sons, L.L.C.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Robert William Levin, M.D.?

Tedicare shows public-source Medicare data for Robert William Levin, M.D. (NPI 1326066903), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Robert William Levin, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Robert William Levin, M.D.?

Robert William Levin, M.D. is linked to AMERICAN ARTHRITIS & RHEUMATOLOGY ASSOCIATES LLC (billing NPI 1598205072) in the available physician profile data.

Does Robert William Levin, M.D. have Open Payments data?

Robert William Levin, M.D. has 334 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.